Prescient Therapeutics (ASX:PTX) completed the first site initiation visit of its phase 2a clinical study of cancer treatment candidate PTX-100, according to a Wednesday filing with the Australian bourse.
The primary endpoint of the study is efficacy, while secondary endpoints include safety, according to the filing.
The study will evaluate two dosage levels of PTX-100 in about 40 patients with relapsed/refractory cutaneous T-cell lymphoma on an open-label basis, the filing said.
Cutaneous T-cell lymphoma is a rare type of non-Hodgkin lymphoma that affects the skin.
Shares rose nearly 7% in afternoon trade Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.